CIBC Private Wealth Group LLC Decreases Stock Position in Bristol-Myers Squibb (NYSE:BMY)

CIBC Private Wealth Group LLC decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 3.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 206,405 shares of the biopharmaceutical company’s stock after selling 8,052 shares during the period. CIBC Private Wealth Group LLC’s holdings in Bristol-Myers Squibb were worth $10,591,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of BMY. AMG National Trust Bank grew its position in Bristol-Myers Squibb by 1.0% during the 3rd quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock worth $1,143,000 after purchasing an additional 201 shares during the last quarter. Westside Investment Management Inc. lifted its stake in shares of Bristol-Myers Squibb by 2.9% during the fourth quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 204 shares during the period. Fulton Breakefield Broenniman LLC grew its holdings in shares of Bristol-Myers Squibb by 4.6% during the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 209 shares during the last quarter. Chapin Davis Inc. increased its position in shares of Bristol-Myers Squibb by 1.2% in the 4th quarter. Chapin Davis Inc. now owns 18,385 shares of the biopharmaceutical company’s stock valued at $943,000 after acquiring an additional 214 shares during the period. Finally, Tilson Financial Group Inc. raised its stake in Bristol-Myers Squibb by 3.7% in the 4th quarter. Tilson Financial Group Inc. now owns 6,258 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 221 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BMY. BMO Capital Markets dropped their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Barclays dropped their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 23rd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $60.00.

Check Out Our Latest Analysis on Bristol-Myers Squibb

Bristol-Myers Squibb Stock Down 1.2 %

Shares of NYSE:BMY opened at $41.25 on Thursday. Bristol-Myers Squibb has a 12-month low of $39.91 and a 12-month high of $66.38. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The stock’s 50-day moving average price is $46.02 and its two-hundred day moving average price is $49.09.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same period in the previous year, the company posted $2.05 earnings per share. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. As a group, equities analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.